Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization
Thermo Fisher Scientific (NYSE: TMO) announced a strategic data collaboration with HealthVerity, the leading real-world...
Ribo Life Science Advances World’s Leading FXI-Targeting siRNA Vortosiran into Phase IIb for AF Stroke Prevention
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted an approval filing...
Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC
Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the...
CureGene’s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial – First Thiol-Based P2Y12 Inhibitor
Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China’s National...
Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that the Phase III clinical trial for...
China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
China Resources Pharmaceutical Commercial Group announced in early March 2026 a strategic cooperation agreement with...
Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating...
China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs...
CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...
Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech
Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to...
Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly
Zuellig Pharma announced on 12 March 2026 the acquisition of all rights, title, and interest...
Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration
Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with...
Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy – RMB 240M Investment Advances CD44/CD133 Autologous Treatment for Recurrent Glioblastoma
Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the...
Mannerchem Secures Exclusive China Rights to Kintor’s AI-Discovered Whitening Ingredient Oximidol KT-939
Mannerchem, the China-based specialty chemicals company, has formed a strategic partnership with domestic biopharmaceutical firm...
Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates
Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China’s National Medical Products...
GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors
GlycoNex, Inc. announced on March 23, 2026, a strategic collaboration agreement with Nippon Kayaku Co.,...
Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M
Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement...
Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration
Menarini Group, the Italian pharmaceutical company, and the Shanghai Angel Baby Charity Foundation have officially...
Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN...
Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years
Sanofi SA (NASDAQ: SNY) announced that the European Commission (EC) has granted marketing authorization for...